2023. 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s232. DOI:https://doi.org/10.25251/skin.7.supp.232.